CN111840510A - 一组食源性多肽的应用 - Google Patents
一组食源性多肽的应用 Download PDFInfo
- Publication number
- CN111840510A CN111840510A CN202010601569.9A CN202010601569A CN111840510A CN 111840510 A CN111840510 A CN 111840510A CN 202010601569 A CN202010601569 A CN 202010601569A CN 111840510 A CN111840510 A CN 111840510A
- Authority
- CN
- China
- Prior art keywords
- seq
- viral
- food
- infectious diseases
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 46
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 44
- 235000013305 food Nutrition 0.000 title claims abstract description 30
- 229920001184 polypeptide Polymers 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 22
- 230000003612 virological effect Effects 0.000 claims abstract description 21
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 20
- 230000036541 health Effects 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
- 241000700605 Viruses Species 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 208000037386 Typhoid Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 201000008297 typhoid fever Diseases 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 230000000711 cancerogenic effect Effects 0.000 claims description 2
- 231100000315 carcinogenic Toxicity 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 230000004083 survival effect Effects 0.000 abstract description 4
- 241000282412 Homo Species 0.000 abstract description 3
- 230000006978 adaptation Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- NTWUFSCNXWKSGG-BOLZHIRLSA-N (2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-methylpentanamide Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 NTWUFSCNXWKSGG-BOLZHIRLSA-N 0.000 description 3
- 108010045514 alpha-lactorphin Proteins 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108010055927 Arg-Pro-Leu-Lys-Pro-Trp Proteins 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 description 2
- PMWSGVRIMIFXQH-KKUMJFAQSA-N His-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)C1=CN=CN1 PMWSGVRIMIFXQH-KKUMJFAQSA-N 0.000 description 2
- XXXXOVFBXRERQL-ULQDDVLXSA-N Leu-Pro-Phe Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XXXXOVFBXRERQL-ULQDDVLXSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 1
- HJGZVLLLBJLXFC-LSJOCFKGSA-N Ala-His-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O HJGZVLLLBJLXFC-LSJOCFKGSA-N 0.000 description 1
- GIVWETPOBCRTND-DCAQKATOSA-N Arg-Gln-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GIVWETPOBCRTND-DCAQKATOSA-N 0.000 description 1
- WKPXXXUSUHAXDE-SRVKXCTJSA-N Arg-Pro-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WKPXXXUSUHAXDE-SRVKXCTJSA-N 0.000 description 1
- GJFYPBDMUGGLFR-NKWVEPMBSA-N Asn-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC(=O)N)N)C(=O)O GJFYPBDMUGGLFR-NKWVEPMBSA-N 0.000 description 1
- QEQVUHQQYDZUEN-GUBZILKMSA-N Asn-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N QEQVUHQQYDZUEN-GUBZILKMSA-N 0.000 description 1
- WLKVEEODTPQPLI-ACZMJKKPSA-N Asp-Gln-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O WLKVEEODTPQPLI-ACZMJKKPSA-N 0.000 description 1
- HKEZZWQWXWGASX-KKUMJFAQSA-N Asp-Leu-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HKEZZWQWXWGASX-KKUMJFAQSA-N 0.000 description 1
- VSMYBNPOHYAXSD-GUBZILKMSA-N Asp-Lys-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O VSMYBNPOHYAXSD-GUBZILKMSA-N 0.000 description 1
- YWLDTBBUHZJQHW-KKUMJFAQSA-N Asp-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N YWLDTBBUHZJQHW-KKUMJFAQSA-N 0.000 description 1
- MYLZFUMPZCPJCJ-NHCYSSNCSA-N Asp-Lys-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MYLZFUMPZCPJCJ-NHCYSSNCSA-N 0.000 description 1
- BVFQOPGFOQVZTE-ACZMJKKPSA-N Cys-Gln-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O BVFQOPGFOQVZTE-ACZMJKKPSA-N 0.000 description 1
- PORWNQWEEIOIRH-XHNCKOQMSA-N Cys-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N)C(=O)O PORWNQWEEIOIRH-XHNCKOQMSA-N 0.000 description 1
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 1
- VNCLJDOTEPPBBD-GUBZILKMSA-N Gln-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N VNCLJDOTEPPBBD-GUBZILKMSA-N 0.000 description 1
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 1
- DGKBSGNCMCLDSL-BYULHYEWSA-N Gly-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN DGKBSGNCMCLDSL-BYULHYEWSA-N 0.000 description 1
- IDQKGZWUPVOGPZ-GUBZILKMSA-N His-Cys-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N IDQKGZWUPVOGPZ-GUBZILKMSA-N 0.000 description 1
- PHIXPNQDGGILMP-YVNDNENWSA-N Ile-Glu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N PHIXPNQDGGILMP-YVNDNENWSA-N 0.000 description 1
- HPCFRQWLTRDGHT-AJNGGQMLSA-N Ile-Leu-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O HPCFRQWLTRDGHT-AJNGGQMLSA-N 0.000 description 1
- KVRKAGGMEWNURO-CIUDSAMLSA-N Leu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N KVRKAGGMEWNURO-CIUDSAMLSA-N 0.000 description 1
- DNDWZFHLZVYOGF-KKUMJFAQSA-N Leu-Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O DNDWZFHLZVYOGF-KKUMJFAQSA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 1
- TVOOGUNBIWAURO-KATARQTJSA-N Lys-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N)O TVOOGUNBIWAURO-KATARQTJSA-N 0.000 description 1
- AWGBEIYZPAXXSX-RWMBFGLXSA-N Met-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N AWGBEIYZPAXXSX-RWMBFGLXSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- FUVBEZJCRMHWEM-FXQIFTODSA-N Pro-Asn-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FUVBEZJCRMHWEM-FXQIFTODSA-N 0.000 description 1
- VEUACYMXJKXALX-IHRRRGAJSA-N Pro-Tyr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VEUACYMXJKXALX-IHRRRGAJSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
- HZZKQZDUIKVFDZ-AVGNSLFASA-N Tyr-Gln-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)O HZZKQZDUIKVFDZ-AVGNSLFASA-N 0.000 description 1
- FEFZWCSXEMVSPO-LSJOCFKGSA-N Val-His-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](C)C(O)=O FEFZWCSXEMVSPO-LSJOCFKGSA-N 0.000 description 1
- XBRMBDFYOFARST-AVGNSLFASA-N Val-His-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N XBRMBDFYOFARST-AVGNSLFASA-N 0.000 description 1
- SDUBQHUJJWQTEU-XUXIUFHCSA-N Val-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C(C)C)N SDUBQHUJJWQTEU-XUXIUFHCSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 108010049589 leucyl-leucyl-leucine Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于生物医药领域，公开了一组食源性多肽的应用，这组多肽的氨基酸序列如序列SEQ ID:1～SEQ ID:23所示，用于制备预防和治疗病毒或细菌感染性疾病药物，以及预防病毒或细菌感染性疾病的特医食品或保健产品。并且，这组多肽尤其均为食源性多肽，它们的来源都可以是人类长期适应环境为生存和繁衍后代的需要而选择形成的食物，用于制备预防和治疗病毒或细菌感染性疾病药物，以及预防病毒或细菌感染性疾病的特医食品或保健产品时，不造成人体的毒副反应，不引起耐药性等负面作用。
Description
技术领域
本发明属于生物医药领域，更具体地，涉及一组食源性多肽的应用，包括这组食源性多肽在制备用于预防和治疗病毒/细菌感染性疾病药物中的应用等，这组食源性多肽它们的氨基酸序列分别如序列SEQ ID:1～SEQ ID:23所示。
背景技术
病毒和细菌是人类生存和发展中存在的重要病原体。要防止病毒和细菌对人细胞的感染和阻止对人体的侵害，根据病毒和细菌传播模式和致病机制，采取有效措施干预。主要有效途径是：1.依据病毒和细菌形态结构和外壳的化学组成，采取有效措施阻挡病毒和细菌对宿主细胞的粘附、入侵和释放。2.明确病毒和细菌遗传物质的基因组结构、表达过程和调控机制，遏制病毒和细菌的遗传物质在寄主细胞内复制表达和产生新一代病毒或细菌。
对于上述第1点，目前采用的办法是用无毒疫苗接种，使人体产生对付病毒的抗体，再就是使用化学药物破坏病毒与寄主细胞的结合和入侵。接种疫苗在人体内产生抗体，是针对已知病毒/细菌才有疗效，对新型变异病毒/细菌没有免疫作用。对于上述第2点，目前也是采用化学药物，干扰病毒和细菌的遗传物质在寄主细胞内合成和复制，从而阻挡病毒颗粒再生及细菌繁殖。但这些化合物往往都有细胞毒性，对人体会有程度轻重的毒副反应。对于细菌，由于抗生素长期使用和过量使用，已产生较强耐药性而失去效用，亟待有新的医药问世。
发明内容
针对现有技术的以上缺陷或改进需求，本发明的目的在于提供一组食源性多肽的应用，用于制备预防和治疗病毒或细菌感染性疾病药物，以及预防病毒或细菌感染性疾病的特医食品或保健产品；并且，这组多肽尤其均为食源性多肽，它们的来源都可以是人类长期适应环境为生存和繁衍后代的需要而选择形成的食物，用于制备预防和治疗病毒或细菌感染性疾病药物，以及预防病毒或细菌感染性疾病的特医食品或保健产品时，能够避免人体的毒副反应，且由于是新药，将能够在较长时间内回避耐细菌/病毒的药性等负面作用。
为实现上述目的，按照本发明的一个方面，提供了一种多肽在制备用于预防和治疗病毒或细菌感染性疾病药物中的应用，其特征在于，所述多肽的氨基酸序列如序列SEQID:1～SEQ ID:23中任意一条所示。
作为本发明的进一步优选，病毒感染性疾病包括流感病毒、冠状病毒、肝炎病毒、鼻炎病毒、艾滋病毒或致癌病毒导致的病毒感染性疾病；
细菌感染性疾病包括感冒、腹泻、肺炎、伤寒、脑膜炎或败血症。
作为本发明的进一步优选，所述药物为口服药物或注射用药物。
作为本发明的进一步优选，所述药物还包括其它辅料。
按照本发明的另一方面，本发明提供了一种用于预防和治疗病毒或细菌感染性疾病药物，其特征在于，包括氨基酸序列如序列SEQ ID:1～SEQ ID:23中任意一条所示的多肽。
按照本发明的又一方面，本发明提供了一种多肽在制备用于预防病毒或细菌感染性疾病的特医食品或保健产品中的应用，其特征在于，所述多肽的氨基酸序列如序列SEQID:1～SEQ ID:23中任意一条所示。
作为本发明的进一步优选，所述特医食品或保健产品还包括其它辅料。
按照本发明的再一方面，本发明提供了一种特医食品或保健产品，其特征在于，包括氨基酸序列如序列SEQ ID:1～SEQ ID:23中任意一条所示的多肽。
通过本发明所构思的以上技术方案，与现有技术相比，由于利用氨基酸序列分别如序列SEQ ID:1～SEQ ID:23所示的一组23种多肽，这些多肽尤其可以是食源性来源，即食源性多肽，能够用于制备预防或治疗病毒或细菌感染性疾病的药物、特医食品或保健产品。这些多肽是由人体必须营养物质氨基酸藉肽键连结成的小蛋白质分子，分子量在250道尔顿至5000道尔顿之间。它们也能作为营养品，提供人体合成蛋白质的氨基酸。它们的来源都可以是人类长期适应环境为生存和繁衍后代的需要而选择形成的食物，无意识地在体内或在体外产生的对人体新陈代谢有正向作用的一类化合物。这类化合物是经过蛋白消化酶水解后的基本单元，在体内能稳定发挥它们的各自功能或联合发挥它们的组合功能。这些小分子多肽，由于其元素组成的丰富和分子内化学键多种巧妙搭配，在人体内能和入侵的病毒和微生物所携带的活性物质发生生物化学反应而阻挡病毒/细菌的入侵和寄生。
附图说明
图1是本发明实施例1中添加有多肽(Gln-Arg-Pro-Arg)时对致病球菌在35℃生长繁殖24小时的实物图。
图2是本发明实施例1中所对比的未添加多肽(Gln-Arg-Pro-Arg)时对致病球菌在35℃生长繁殖24小时的实物图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合实施例，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施例仅仅用以解释本发明，并不用于限定本发明。此外，下面所描述的本发明各个实施方式中所涉及到的技术特征只要彼此之间未构成冲突就可以相互组合。
总的说来，本发明中的一组食源性多肽，它们的氨基酸序列如下：
Ala-His-Val-His；
Arg-Ala-Asp-His-Pro-Phe-Leu；
Asp-Lys-Glu-Asn；
Arg-Pro-Leu-Lys-Pro-Trp；
Arg-Gln-Arg-Lys；
Cys-Gln-Pro-Pro-Asn-Ser-Lys-Thr-Cys；
Cys-Gln-Ala-Pro-Tyr-Ser-Leu-Ala-Cys；
Gln-Arg-Pro-Arg；
His-Cys-Gln-Arg-Pro-Arg；
His-His-Leu；
Ile-Glu-Glu-Gln-Cys-Lys-Thr-Phe-Leu-Asp-Lys-Phe-Asn-His-Glu-Ala-Glu-Asp-Glu-Asp-Leu-Phe-Tyr-Gln-Ser；
Ile-Leu-Leu；
Leu-Pro-Phe；
Lys-Leu-Lys-Leu-Leu-Lys-Leu-Lys；
Leu-Leu-Leu；
Leu-Leu-Pro-His-His；
Met-Leu-Pro-Ser-Tyr-Ser-Pro-Tyr；
Tyr-Ala-Gln-Glu-Arg-Tyr-Pro-Ile-Leu；
Val-His-Ala-Asp-Gln-Asn；
Val-His-Val-Val；
Val-Ile-Lys；
Asp-Lys-Val-Gly-Ile-Asn-Tyr-Trp；
Tyr-Gly-Leu-Phe；
共计23个多肽。
这些食源性多肽，来治疗病毒和细菌感染性疾病，包含流感病毒，冠状病毒，肝炎病毒，鼻炎病毒，艾滋病毒和致癌病毒等病毒感染性疾病以及由致病细菌感染而产生的疾病如感冒、腹泻、肺炎、伤寒和脑膜炎等等。例如，可以用上述单一或一个以上的多肽合并制造药品，供口服或注射用。又例如，可以用上述单一或一个以上多肽合并制造特医食品或保健产品。当然，也可以用上述单一或一个以上多肽和其它物料混合制造药品，供口服或注射用。或者，用上述单一或一个以上多肽和其它物料混合制造特医食品或保健产品。
以下为具体实施例：
实施例1.
对同样一种致病球菌，加了肽Gln-Arg-Pro-Arg(15微克/毫升)培养时，细菌在35℃生长繁殖24小时明显少于未加这个肽的菌落数(如图1、图2对比所示)。
实施例2.
2018冬至2019春，有家幼儿园闹流行性感冒。经流行病学调查，有83个孩子喝酸奶，只有9个患上感冒，患病率11％。而不喝酸奶的小孩有15个，有5个患了流感，发病率占33％。这是因为酸奶中含有Asp-Lys-Val-Gly-Ile-Asn-Tyr-Trp、Tyr-Gly-Leu-Phe等抗菌抗病毒及消炎提高免疫力的肽存在。
本发明所采用的氨基酸序列分别如序列SEQ ID:1～SEQ ID:23所示的这一组多肽，尤其可以是食源性多肽，合成途径例如可以如下：如普通牛奶的酪蛋白中含有一个如下较大的多肽Asn-Gly-Pro-Glu-Pro-Ser-Gly-Pro-Glu-Pro-Glu-Pro,将牛奶发酵制备成酸奶，在加工过程中受乳酸菌复合蛋白酶作用，可将其水解成Asn-Gly-Pro、Glu-Pro、Ser-Gly-Pro、Glu-Pro等小肽，从而食源性的获得多肽。
本领域的技术人员容易理解，以上所述仅为本发明的较佳实施例而已，并不用以限制本发明，凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明的保护范围之内。
序列表
<110> 华中科技大学
<120> 一组食源性多肽的应用
<160> 23
<170> SIPOSequenceListing 1.0
<210> 1
<211> 4
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ala His Val His
1
<210> 2
<211> 7
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Arg Ala Asp His Pro Phe Leu
1 5
<210> 3
<211> 4
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Asp Lys Glu Asn
1
<210> 4
<211> 6
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Arg Pro Leu Lys Pro Trp
1 5
<210> 5
<211> 4
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Arg Gln Arg Lys
1
<210> 6
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Cys Gln Pro Pro Asn Ser Lys Thr Cys
1 5
<210> 7
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Cys Gln Ala Pro Tyr Ser Leu Ala Cys
1 5
<210> 8
<211> 4
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Gln Arg Pro Arg
1
<210> 9
<211> 6
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 9
His Cys Gln Arg Pro Arg
1 5
<210> 10
<211> 3
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 10
His His Leu
1
<210> 11
<211> 25
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Ile Glu Glu Gln Cys Lys Thr Phe Leu Asp Lys Phe Asn His Glu Ala
1 5 10 15
Glu Asp Glu Asp Leu Phe Tyr Gln Ser
20 25
<210> 12
<211> 3
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Ile Leu Leu
1
<210> 13
<211> 3
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Leu Pro Phe
1
<210> 14
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Lys Leu Lys Leu Leu Lys Leu Lys
1 5
<210> 15
<211> 3
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 15
Leu Leu Leu
1
<210> 16
<211> 5
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 16
Leu Leu Pro His His
1 5
<210> 17
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 17
Met Leu Pro Ser Tyr Ser Pro Tyr
1 5
<210> 18
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 18
Tyr Ala Gln Glu Arg Tyr Pro Ile Leu
1 5
<210> 19
<211> 6
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 19
Val His Ala Asp Gln Asn
1 5
<210> 20
<211> 4
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 20
Val His Val Val
1
<210> 21
<211> 3
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 21
Val Ile Lys
1
<210> 22
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 22
Asp Lys Val Gly Ile Asn Tyr Trp
1 5
<210> 23
<211> 4
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 23
Tyr Gly Leu Phe
1
Claims (8)
1.一种多肽在制备用于预防和治疗病毒或细菌感染性疾病药物中的应用，其特征在于，所述多肽的氨基酸序列如序列SEQ ID:1～SEQ ID:23中任意一条所示。
2.如权利要求1所述应用，其特征在于，病毒感染性疾病包括流感病毒、冠状病毒、肝炎病毒、鼻炎病毒、艾滋病毒或致癌病毒导致的病毒感染性疾病；
细菌感染性疾病包括感冒、腹泻、肺炎、伤寒、脑膜炎或败血症。
3.如权利要求1或2所述应用，其特征在于，所述药物为口服药物或注射用药物。
4.如权利要求1至3任意一项所述应用，其特征在于，所述药物还包括其它辅料。
5.一种用于预防和治疗病毒或细菌感染性疾病药物，其特征在于，包括氨基酸序列如序列SEQ ID:1～SEQ ID:23中任意一条所示的多肽。
6.一种多肽在制备用于预防病毒或细菌感染性疾病的特医食品或保健产品中的应用，其特征在于，所述多肽的氨基酸序列如序列SEQ ID:1～SEQ ID:23中任意一条所示。
7.如权利要求6所述应用，其特征在于，所述特医食品或保健产品还包括其它辅料。
8.一种特医食品或保健产品，其特征在于，包括氨基酸序列如序列SEQ ID:1～SEQ ID:23中任意一条所示的多肽。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010601569.9A CN111840510A (zh) | 2020-06-28 | 2020-06-28 | 一组食源性多肽的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010601569.9A CN111840510A (zh) | 2020-06-28 | 2020-06-28 | 一组食源性多肽的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111840510A true CN111840510A (zh) | 2020-10-30 |
Family
ID=72989245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010601569.9A Pending CN111840510A (zh) | 2020-06-28 | 2020-06-28 | 一组食源性多肽的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111840510A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112656934A (zh) * | 2021-01-22 | 2021-04-16 | 深圳市图微安创科技开发有限公司 | 多肽at03在治疗原发性胆汁性胆管炎药物中的应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0692867A (ja) * | 1992-03-04 | 1994-04-05 | Honen Corp | 免疫系賦活剤 |
| CN1582400A (zh) * | 2001-02-21 | 2005-02-16 | 加拿大国立研究院 | 用于微生物鉴定和分类的磁共振波谱分析 |
| CN1893911A (zh) * | 2003-11-17 | 2007-01-10 | 赛德玛公司 | 含有四肽和三肽混合物的配方 |
| WO2009033784A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| CN102178040A (zh) * | 2011-04-27 | 2011-09-14 | 黑龙江省大豆技术开发研究中心 | 一种含有大豆免疫肽的饲料添加剂及其制备方法和应用 |
| CN103288931A (zh) * | 2012-02-24 | 2013-09-11 | 宋硕 | 人类乳头瘤病毒免疫原性多肽、其制备方法及应用 |
-
2020
- 2020-06-28 CN CN202010601569.9A patent/CN111840510A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0692867A (ja) * | 1992-03-04 | 1994-04-05 | Honen Corp | 免疫系賦活剤 |
| CN1582400A (zh) * | 2001-02-21 | 2005-02-16 | 加拿大国立研究院 | 用于微生物鉴定和分类的磁共振波谱分析 |
| CN1893911A (zh) * | 2003-11-17 | 2007-01-10 | 赛德玛公司 | 含有四肽和三肽混合物的配方 |
| WO2009033784A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| CN102178040A (zh) * | 2011-04-27 | 2011-09-14 | 黑龙江省大豆技术开发研究中心 | 一种含有大豆免疫肽的饲料添加剂及其制备方法和应用 |
| CN103288931A (zh) * | 2012-02-24 | 2013-09-11 | 宋硕 | 人类乳头瘤病毒免疫原性多肽、其制备方法及应用 |
Non-Patent Citations (5)
| Title |
|---|
| MASAAKI YOSHIKAWA等: "Immunostimulating Peptide Derived from Soybean Protein", 《ANNALS NEW YORK ACADEMY OF SCIENCES》 * |
| TOLULOPE JOSHUA ASHAOLU: "Health Applications of Soy Protein Hydrolysates", 《INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS》 * |
| 王依楠: "大豆寡肽QRPR激活自噬抑制RAW264.7细胞炎症的机制研究", 《中国优秀博硕士学位论文全文数据库(硕士) 工程科技Ⅰ辑》 * |
| 王琳: "大豆寡肽（QRPR、HCQRPR）对Hep G2细胞凋亡的作用及机制的研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
| 马萍主编: "《医学免疫学与病原生物学（第3版）》", 31 August 2019 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112656934A (zh) * | 2021-01-22 | 2021-04-16 | 深圳市图微安创科技开发有限公司 | 多肽at03在治疗原发性胆汁性胆管炎药物中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3100005B2 (ja) | ヒト免疫不全ウィルス感染・増殖抑制剤 | |
| CN114181293B (zh) | 一种人源抗菌肽ll-37改造体及其应用 | |
| JP2003528827A5 (zh) | ||
| JP2003528827A (ja) | カゼイン由来ペプチドおよびその医療用途 | |
| SG191287A1 (en) | Antimicrobial fusion compounds and uses thereof | |
| JP2001510805A (ja) | リソスタフィン単独含有もしくは抗生物質併用ブドウ球菌感染症治療用薬剤組成物 | |
| CN107312760B (zh) | 一种n-酰基高丝氨酸内酯酶及其药物 | |
| WO2023155342A1 (zh) | 一种用于防治呼吸道疾病的雾化吸入制剂及其应用 | |
| CN102939301A (zh) | 作为抗菌剂使用的肽化合物 | |
| CN101254304A (zh) | 用于治疗微生物感染的药物及其用途 | |
| CN111840510A (zh) | 一组食源性多肽的应用 | |
| CN114989254B (zh) | 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 | |
| CN110256556A (zh) | 一种耐甲氧西林金黄色葡萄球菌人免疫球蛋白及制备方法 | |
| CN111500609A (zh) | 一种抗白色念球菌重组抗原及卵黄抗体的制备方法和用途 | |
| CN101878226B (zh) | 精氨酸取代的新型合成肽及其应用 | |
| CN109289046A (zh) | 一种具核梭杆菌FomA蛋白质疫苗以及制备方法和应用 | |
| JPH06503364A (ja) | 髄膜炎菌“Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ”感染症に対するサブユニットワクチンと、精製状態での対応サブユニット | |
| WO2020108427A1 (zh) | 一种新型干扰素α及其制备方法、组合物和用途 | |
| CN107224582A (zh) | 免疫增强肽在制备通过粘膜给药的增强免疫功能药物中的应用 | |
| CN111346212A (zh) | 活性多肽在制备抗冠状病毒药物及医用食品中的应用 | |
| Sarfaraz et al. | Recent updates on peptide molecules in drug and vaccine development | |
| CN111848817A (zh) | 一种兼具抗菌、抗病毒、免疫调节和抗炎活性的多功能杂合肽及其制备方法和应用 | |
| CN110669146B (zh) | 一种可特异性阻断衔接蛋白Nck的结合位点用于预防肠道EPEC感染的活性肽 | |
| Ruziaki et al. | Unusual pathogen Comamonas testosteroni sepsis following gastroenteritis in a 12 months old child: Case report and literature review | |
| CN103933554B (zh) | 一种用于预防猪口蹄疫的干扰素白油组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201030 |
|
| RJ01 | Rejection of invention patent application after publication |